About Avalon Bio Ventures
Avalon Bio Ventures is a venture capital firm founded in 1983. It is primarily based out of San Diego, United States. As of Sep 2025, Avalon Bio Ventures is an active investor, having invested in 19 companies, with 1 new investment in the last 12 months. It primarily invests in Series A round in United States based startups. Its investments are spread across a wide range of sectors from Life Sciences to Enterprise Applications and HealthTech. Most recently it participated in the $***** Series A round of AeroRx Overall, Avalon Bio Ventures portfolio has seen 1 IPO and 4 acquisitions including key companies like Janux Therapeutics, Aratana Therapeutics and Synthorx. A lot of funds co-invest with Avalon Bio Ventures, with names like Correlation Ventures sharing a substantial percentage of its portfolio. Avalon Bio Ventures has team of 13 people including 5 partners.Key Metrics
Team Members
Portfolio Count
Portfolio Sectors
Portfolio Locations
Rounds of Entry
Series A & Seed
Portfolio IPOs
Portfolio Acquisitions
Portfolio Soonicorns
Deals in last 12 months
Avalon Bio Ventures' List of Top Investments
Avalon Bio Ventures has a portfolio of 19 companies. Their most notable investments are in Arialys and Valora Therapeutics.Their portfolio spans across and United States. They have invested in Life Sciences, Enterprise Applications, HealthTech and 2 other sectors, across stages such as Series A, Seed stages. Here is the list of top investments by Avalon Bio Ventures:Developer of immunotherapeutics for the treatment of cancer. The company's lead candidates include TROP2-TRACTr, PSMA-TRACTr, EGFR-TRACTr, HER2-TRACTr, and Costim bispecific. The company is developing drugs to treat solid tumours including colorectal, gastroesophageal, prostrate, NSCLC, triple-negative breast, and ovarian cancers. It is also developing T cell engagers (TCEs) that bind to a tumour cell and engage a patient’s T-cells to eradicate the tumour.
Key facts about Janux Therapeutics
- Founded Year: 2017
- Location: San Diego (United States)
- Annual Revenue: $10M - $50M as on Dec 31, 2025
- Stage: Public
- Total Funding till date: $181M
- Employee Count: 118 as on May 31, 2026
- Investors: Janus Henderson Investors, BVF Partners and 10 Others
- Latest Funding Round: Series B, Apr 20, 2021, $*****
- Highlight: Public
2. AristaMD
Provider of specialist e-consults and referral platform for healthcare providers. It is a digital health company focused on improving the specialty referral process. It offers simple-to-use software and eConsult solutions for better specialty referral decisions, reduced cost-of-care, and improved patient outcomes.
Key facts about AristaMD
- Founded Year: 2014
- Location: San Diego (United States)
- Stage: Series B
- Total Funding till date: $61.6M
- Employee Count: 78 as on May 31, 2026
- Investors: MemorialCare Innovation Fund, Cigna Ventures and 11 Others
- Latest Funding Round: Series B, Mar 04, 2022, $*****
- Highlight: Editors' Pick
3. Arialys
It is a private biotech company focused on developing new precision medicines for autoimmune neuropsychiatric diseases. They are exploring scientific breakthroughs in this field and aim to provide therapeutic solutions for those affected by these conditions.
Key facts about Arialys
- Founded Year: 2021
- Location: La Jolla (United States)
- Stage: Seed
- Total Funding till date: $72.8M
- Employee Count: 15 as on Mar 31, 2026
- Investors: Alexandria, Catalys Pacific and 2 Others
- Latest Funding Round: Seed, Jun 13, 2025, $*****
Aratana Therapeutics is a developer of pet therapeutics. It has drugs in the development stage to ease the ongoing pain and inflammation of osteoarthritis or degenerative joint disease in pets. Also has medicines in development to treat inappetence, cancer, & viral infections in pets (dogs & cats).
Key facts about Aratana Therapeutics
- Founded Year: 2010
- Location: United States
- Stage: Acquired
- Total Funding till date: $47M
- Employee Count: 16 as on May 31, 2026
- Investors: Square 1 Bank, Cultivian Sandbox and 9 Others
- Latest Funding Round: Conventional Debt, Oct 16, 2015, $*****
- Highlight: Acquired
5. Synthorx
Provider of solutions for drug discovery, diagnostics, and vaccines using a synthetic DNA base pair. The company has synthesized several unnatural bases, which would expand the genetic alphabet and provide in vitro biotechnology applications. The bases get PCR amplified with the same efficiency and fidelity and require a 'base transporter' protein to be transported into the cell.
Key facts about Synthorx
- Founded Year: 2014
- Location: San Diego (United States)
- Stage: Acquired
- Total Funding till date: $79M
- Employee Count: 5 as on May 31, 2026
- Investors: Orbimed, Avalon Ventures and 5 Others
- Latest Funding Round: Series C, Apr 30, 2018, $*****
- Highlight: Acquired
Avalon Bio Ventures' Year-on-Year Investment Trends
Avalon Bio Ventures has invested in 19 companies over the last 18 years, with an average of 0 new investment annually in the last 10 years. In 2025, it made 1 investment. Its most recent first time investment was in AeroRx and most recent follow-on round was in Fortis Therapeutics.Year | No. of Investments | ||
|---|---|---|---|
1st Round | Follow-on | Total | |
2026 (YTD) | 0 | 0 | 0 |
2025 | 1 | 0 | 1 |
2024 | 1 | 0 | 1 |
2023 | 1 | 0 | 1 |
2022 | 0 | 0 | 0 |
2021 | 0 | 1 | 1 |
Avalon Bio Ventures' Investments by Stage
Avalon Bio Ventures has made 6 investments in Series A stage with an average round size of $13.5M and 2 investments in Seed stage with an average round size of $44M.Stage of entry | No. of Investments |
|---|---|
Series A | 6 |
Seed | 2 |
Note: We have considered here, only first round of investments
Avalon Bio Ventures' Investments by Sector
Avalon Bio Ventures has a diverse portfolio, with companies operating in the Life Sciences, Enterprise Applications, Healthcare and HealthTech. Notably, it has invested in 16 Tech companies, 14 Enterprise (B2B) companies, 4 Software companies and 1 company focusing on Saas.Sector | No. of Investments |
|---|---|
Life Sciences | 5 |
Enterprise Applications | 2 |
Healthcare | 2 |
HealthTech | 1 |
Note: We have considered here, only first round of investments
Avalon Bio Ventures' Investments by Geography
Avalon Bio Ventures has made most investments in United States (8).Avalon Bio Ventures' recent investments
Avalon Bio Ventures has not made any investment in 2026 so far.Here are the most recent investments by Avalon Bio Ventures:
Filter this listDate | Company | Location | Round Details | Round Amount | Co-Investors |
|---|---|---|---|---|---|
Sep 25, 2025 | United States | Series A | 4039 | [+1] | |
Jul 09, 2024 | United States | Seed | 5299 | [+3] | |
Sep 12, 2023 | United States | Seed | 9892 | [+2] | |
Mar 29, 2021 | United States | Series A | 2355 | [+6] | |
Sep 27, 2016 | United States | Series A | 5931 | [+2] |
IPOs and Publicly Listed companies in Avalon Bio Ventures' Portfolio
1 of Avalon Bio Ventures' portfolio company became public - Janux Therapeutics. It got listed on the National Association of Securities Dealers Automated Quotations (NASDAQ), in Jun 2021 at marketcap of $678MHere are Avalon Bio Ventures' portfolio companies that went public:
Company | IPO Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
Jun 11, 2021 | - | - | 3948 |
Acquired companies in Avalon Bio Ventures' Portfolio
4 companies from Avalon Bio Ventures' portfolio have been acquired. The most recent acquisition was Synthorx in Dec 2019 by Sanofi for $*****.Here are Avalon Bio Ventures' portfolio companies that got acquired most recently:
Company | Acquisition Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
Dec 09, 2019 | - | - | 8662 | |
Apr 26, 2019 | Jan 07, 2011 | Series A | 1891 | |
Feb 12, 2013 | - | - | 9158 | |
Jan 07, 2013 | Nov 08, 2008 | Series A | 5041 |
Team profile of Avalon Bio Ventures
Avalon Bio Ventures has a team of 13 members including 5 Partners and 2 Principals located in United States. Avalon Bio Ventures' team sits on the board of 1 company.Here is a list of top team members in Avalon Bio Ventures:
Name | Designation | Location | Board Memberships | Contact Details |
|---|---|---|---|---|
Partner | San Diego | - | ||
Partner | San Diego | - | ||
Partner | Rancho Santa Fe | |||
Partner | - | - | - | |
Partner | - | - | - | |
Principal | - | - | ||
Principal | San Diego | - |
Co-investors of Avalon Bio Ventures
Over the past 18 years, 37 investors have co-invested in Avalon Bio Ventures's portfolio companies. This includes only funds.
- Invested before Avalon Bio Ventures: HHS has invested before Avalon Bio Ventures.
- Top Co-investors of Avalon Bio Ventures: 12 investors entered a company along with Avalon Bio Ventures. These include investors like Correlation Ventures (3 companies).
- Invested after Avalon Bio Ventures: A total of 24 investors have invested in Avalon Bio Ventures's portfolio after their investments. Top Investors include Cobalt Ventures (1 company), .406 Ventures (1 company) and Ascension (1 company).
Recent News related to Avalon Bio Ventures
•
AeroRx Therapeutics Raises $21M in Series A FinancingFinSMEs•Oct 08, 2025•Avalon Bio Ventures, Alexandria, Correlation Ventures, AeroRx
•
•
Neuro Startup Arialys Raises $58M for Privilege of Tackling Brain InflammationMedCity News•Sep 13, 2023•Arialys, Avalon Bio Ventures, Astellas Pharma, Catalys Pacific and 2 others
•
Arialys Therapeutics Launches to Lead the Development of New Precision Medicines for Autoimmune Neuropsychiatric DiseasesBusiness Wire•Sep 12, 2023•Arialys, Avalon Bio Ventures, Catalys Pacific, MPM BioImpact and 2 others
•
Avalon BioVentures Raises First Fund Dedicated to Early-Stage Biotech InvestmentsBusiness Wire•Dec 06, 2022•Avalon Bio Ventures
•
•
COI Pharmaceuticals Announces Acquisition of Calporta by MerckBusiness Wire•Nov 13, 2019•Merck, Avalon Bio Ventures, Calporta Therapeutics, COI Pharma and 1 other
•
•
•
